<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028179</url>
  </required_header>
  <id_info>
    <org_study_id>COL-69</org_study_id>
    <nct_id>NCT05028179</nct_id>
  </id_info>
  <brief_title>PROTEUS: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease</brief_title>
  <acronym>PROTEUS</acronym>
  <official_title>PROTEUS: A PROspective Randomised Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultromics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford Academic Health Science Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ultromics Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROTEUS is a multicentre, two arm, randomised controlled trial of a medical device to assess&#xD;
      the impact of the introduction of EchoGo into the standard care pathway for stress&#xD;
      echocardiology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multi-centre, two-arm, randomised controlled trial. Randomised 1:1&#xD;
Standard care group (comparator)&#xD;
Standard care plus AI platform (EchoGo)</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Following the stress echocardiogram examination, participants will follow the care pathway determined by the clinical team managing their care. If the participant is assigned to the study intervention arm the EchoGo report will inform this decision making process.&#xD;
In order to minimise bias in any outcome assessment clinicians will be asked not to share the details of the EchoGo report received for participants within the intervention arm with the participant or with colleagues who may undertake future investigations eg: angiography.If a clinician subsequently considers there is a clinical need to know the details of the EchoGo report this can be made available at the discretion of the study team.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate if EchoGo plus standard care is non-inferior to standard care alone in predicting the risk of cardiovascular disease following stress echocardiogram (SE)</measure>
    <time_frame>6 months post stress echo</time_frame>
    <description>Outcome shall be measured through the assessment of appropriate clinical management at 6 months following stress echocardiogram.&#xD;
Appropriate management will be defined as a composite of&#xD;
coronary angiography that demonstrates severe coronary disease fulfilling clinical care guidelines for revascularisation or&#xD;
decision for medical management/reassurance without unanticipated serious adverse cardiac events Outcome data will be collected from participant's medical records at 3 and 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate if EchoGo plus standard care is superior to standard care alone in predicting the risk of severe cardiovascular disease following stress echocardiogram (SE)</measure>
    <time_frame>6 month post stress echo</time_frame>
    <description>Outcome shall be measured through the assessment of appropriate clinical management at 6 months following stress echocardiogram.&#xD;
Appropriate management will be defined as a composite of&#xD;
coronary angiography that demonstrates severe coronary disease fulfilling clinical care guidelines for revascularisation or&#xD;
decision for medical management/reassurance without unanticipated serious adverse cardiac events Outcome data will be collected from participant's medical records at 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish if deploying the EchoGo Platform into NHS sites affects the number of unanticipated serious cardiac events</measure>
    <time_frame>6 month</time_frame>
    <description>The outcome shall be measures through collection of the number of acute coronary events not related to elective cardiac procedures occurring up to 6 months following SE.&#xD;
Acute coronary events are defined as:&#xD;
Myocardial Infarction Type 3 (ESC universal definition)&#xD;
Hospital admission with Myocardial Infarction Type 1 (ESC universal definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish if clinical management decision making is affected by review of the EchoGo report.</measure>
    <time_frame>6 month</time_frame>
    <description>Establish if clinical management decision making is affected by review of the EchoGo report as recorded by clinician self-report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish if using the EchoGo platform affects clinician diagnostic confidence.</measure>
    <time_frame>3 and 6 months post stress echo</time_frame>
    <description>Clinician diagnostic confidence in their interpretation of the stress echo report will be measured by clinician self-report at baseline, 3 months and end of study at each participating site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish if clinician diagnostic performance variance reduces with EchoGo use.</measure>
    <time_frame>3 and 6 month post stress echo</time_frame>
    <description>Outcome measured by Inter-clinician and in-site variability at baseline, 3 months and at end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish if using Ultromics' EchoGo Platform affects the number of subsequent investigations for cardiovascular disease. for cardiovascular disease</measure>
    <time_frame>3 and 6 months post stress echo</time_frame>
    <description>Outcome shall be measured through collation of the number of incidences of the following (occurring up to 6 months following stress echo):&#xD;
Myocardial Perfusion Scan&#xD;
CT coronary angiogram&#xD;
Stress echo&#xD;
Invasive coronary angiogram&#xD;
Stress CMR&#xD;
Exercise tolerance test&#xD;
Initiation of anti-anginal medication/medical management of angina&#xD;
Data will be collected from participants medical records at 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish if using Ultromics' EchoGo Platform affects patient reported coronary artery disease symptoms.</measure>
    <time_frame>3 and 6 months post stress echo</time_frame>
    <description>Outcome shall be measured through the collation of the number of coronary artery disease symptoms and impact on participant health status as measured by patient-reported short Seattle Angina Questionnaire (SAQ-7) at trial entry, 3 months and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the health economics impact of implementation and use of Ultromics' EchoGo platform in NHS units</measure>
    <time_frame>3 and 6 month post stress echo</time_frame>
    <description>Intervention cost benefit as defined by individual-level data conducted from the health system perspective from randomisation to follow-up at 6 months. Change in health-related Quality of Life (measured by patient-reported EQ-5D-5L at trial entry, 3 months and 6 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Standard Care (comparator)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care plus AI platform (EchoGo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EchoGo</intervention_name>
    <description>EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD</description>
    <arm_group_label>Standard Care plus AI platform (EchoGo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Male or female, â‰¥18 years of age at study entry&#xD;
&#xD;
          -  Referred to an NHS Trust for stress echocardiography for investigation of ischaemic&#xD;
             heart disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than moderate valvular heart disease&#xD;
&#xD;
          -  Left ventricular outflow tract obstruction defined as a gradient &gt; 30mmHg (fixed or&#xD;
             dynamic; supravalvular, valvular or sub-valvular)&#xD;
&#xD;
          -  Significant co-morbidities (e.g. cancer) with an expected life-expectancy of under 12&#xD;
             months in the investigator's opinion&#xD;
&#xD;
          -  Previous coronary artery bypass graft or other cardiac surgery&#xD;
&#xD;
          -  Congenital or inherited myocardial disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gary Woodward, PhD</last_name>
    <phone>07515998737</phone>
    <email>PROTEUS@ultromics.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

